[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TW200510332A - Benzimidazolone compounds having 5-HT4 receptor agonistic activity - Google Patents

Benzimidazolone compounds having 5-HT4 receptor agonistic activity

Info

Publication number
TW200510332A
TW200510332A TW093126507A TW93126507A TW200510332A TW 200510332 A TW200510332 A TW 200510332A TW 093126507 A TW093126507 A TW 093126507A TW 93126507 A TW93126507 A TW 93126507A TW 200510332 A TW200510332 A TW 200510332A
Authority
TW
Taiwan
Prior art keywords
disease
dyspepsia
compounds
agonistic activity
receptor agonistic
Prior art date
Application number
TW093126507A
Other languages
English (en)
Inventor
Satoru Iguchi
Yasuhiro Katsu
Hiroki Sone
Chikara Uchida
Takashi Kojima
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TW200510332A publication Critical patent/TW200510332A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Manufacturing & Machinery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ceramic Engineering (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW093126507A 2003-09-03 2004-09-02 Benzimidazolone compounds having 5-HT4 receptor agonistic activity TW200510332A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50014403P 2003-09-03 2003-09-03

Publications (1)

Publication Number Publication Date
TW200510332A true TW200510332A (en) 2005-03-16

Family

ID=34272920

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093126507A TW200510332A (en) 2003-09-03 2004-09-02 Benzimidazolone compounds having 5-HT4 receptor agonistic activity

Country Status (40)

Country Link
US (2) US7776885B2 (zh)
EP (1) EP1664036B1 (zh)
JP (1) JP3983269B1 (zh)
KR (1) KR100738784B1 (zh)
CN (1) CN100482659C (zh)
AP (1) AP2184A (zh)
AR (1) AR045552A1 (zh)
AT (1) ATE539077T1 (zh)
AU (1) AU2004268840B9 (zh)
BR (1) BRPI0414105B8 (zh)
CA (1) CA2537127C (zh)
CR (1) CR8267A (zh)
CY (1) CY1112321T1 (zh)
DK (1) DK1664036T3 (zh)
EA (1) EA009457B1 (zh)
EC (1) ECSP066407A (zh)
ES (1) ES2377484T3 (zh)
GE (1) GEP20084527B (zh)
GT (1) GT200400174A (zh)
HK (1) HK1093338A1 (zh)
HR (1) HRP20120077T1 (zh)
IL (3) IL173705A (zh)
IS (1) IS8289A (zh)
MA (1) MA28021A1 (zh)
MX (1) MXPA06002550A (zh)
NL (1) NL1026959C2 (zh)
NO (1) NO20061519L (zh)
OA (1) OA13248A (zh)
PA (1) PA8610601A1 (zh)
PE (1) PE20050874A1 (zh)
PL (1) PL1664036T3 (zh)
PT (1) PT1664036E (zh)
RS (1) RS20060145A (zh)
SI (1) SI1664036T1 (zh)
TN (1) TNSN06073A1 (zh)
TW (1) TW200510332A (zh)
UA (1) UA86204C2 (zh)
UY (1) UY28496A1 (zh)
WO (1) WO2005021539A1 (zh)
ZA (1) ZA200601324B (zh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE241351T1 (de) 1996-07-24 2003-06-15 Warner Lambert Co Isobutylgaba und dessen derivate zur schmerzbehandlung
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
AP2184A (en) * 2003-09-03 2010-12-02 Pfizer Benzimidazolone compounds having 5-HT4 receptor agonistic activity.
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
EA010891B9 (ru) 2004-06-15 2012-08-30 Пфайзер Инк. Производные бензимидазолонкарбоновой кислоты
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
WO2006052889A2 (en) 2004-11-05 2006-05-18 Theravance, Inc. Quinolinone-carboxamide compounds
ES2332808T3 (es) 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
WO2006069125A1 (en) 2004-12-22 2006-06-29 Theravance, Inc. Indazole-carboxamide compounds
KR100908547B1 (ko) * 2005-02-22 2009-07-20 화이자 인코포레이티드 ５ｈｔ４ 수용체 작용제로서의 옥시인돌 유도체
KR20070107807A (ko) 2005-03-02 2007-11-07 세라밴스 인코포레이티드 5-ｈｔ4 수용체 아고니스트인 퀴놀리논 화합물
EP1861377B1 (en) 2005-03-15 2010-12-29 Pfizer, Inc. Benzimidazolone derivatives as cb2 receptor ligands
MY147756A (en) 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
ATE495171T1 (de) * 2005-06-07 2011-01-15 Theravance Inc Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors
EP1960389B1 (en) 2005-09-30 2012-08-15 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2007036711A1 (en) * 2005-09-30 2007-04-05 Glaxo Group Limited BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR
AU2006296369B2 (en) * 2005-09-30 2012-12-20 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
CA2625210A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
MY143574A (en) * 2005-11-22 2011-05-31 Theravance Inc Carbamate compounds as 5-ht4 receptor agonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
WO2007086541A2 (en) * 2006-01-24 2007-08-02 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
US20080318964A1 (en) * 2007-06-19 2008-12-25 Protia, Llc Deuterium-enriched eszopiclone
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
EP2496228B1 (en) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
ES2640752T3 (es) * 2010-02-12 2017-11-06 Askat Inc. Agonistas del receptor 5-HT4 para el tratamiento de la demencia
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US20120143119A1 (en) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of Serotonin Receptor Antagonists By Microinjection Systems
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
EP2852591A1 (en) 2012-05-03 2015-04-01 Novartis AG L-malate salt of 2, 7 - diaza - spiro [4.5]dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
US20180344648A1 (en) * 2015-11-30 2018-12-06 Piramal Enterprises Limited Clobazam tablet formulation and process for its preparation
EP4232001A4 (en) * 2020-10-23 2024-09-18 Hk Inno N Corp ORALLY DISINTEGRATING TABLET COMPRISING BENZIMIDAZOLE DERIVED COMPOUND AND PREPARATION METHOD THEREOF

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US63716A (en) * 1867-04-09 Improved cheery stoner
CH566987A5 (zh) * 1972-04-21 1975-09-30 Ciba Geigy Ag
US3945953A (en) * 1972-04-21 1976-03-23 Ciba-Geigy Corporation ω,ω'-Bis-[4-amino-3-aminomethyl-piperidyl-(1)]-alkanes, process for their manufacture and their use
DE3336024A1 (de) * 1983-10-04 1985-04-18 Boehringer Ingelheim KG, 6507 Ingelheim 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0522914A1 (fr) * 1991-06-27 1993-01-13 Synthelabo Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
GB9204565D0 (en) 1992-03-03 1992-04-15 Smithkline Beecham Plc Pharmaceuticals
US5300512A (en) 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
WO1994010174A1 (en) 1992-11-05 1994-05-11 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
TW252206B (zh) * 1993-09-01 1995-07-21 Philips Electronics Nv
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2303438A1 (en) 1997-09-09 1999-03-18 Bristol-Myers Squibb Pharma Company Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
US6420410B1 (en) * 1998-11-24 2002-07-16 Cell Pathways, Inc. Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
TW570920B (en) 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
WO2002053568A1 (fr) * 2000-12-28 2002-07-11 Mochida Pharmaceutical Co., Ltd. Inhibiteurs de la biosynthese du cholesterol contenant comme principe actif des composes spiro tricycliques
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
AP2184A (en) * 2003-09-03 2010-12-02 Pfizer Benzimidazolone compounds having 5-HT4 receptor agonistic activity.
EA010891B9 (ru) * 2004-06-15 2012-08-30 Пфайзер Инк. Производные бензимидазолонкарбоновой кислоты
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
PT1664036E (pt) 2012-02-16
IS8289A (is) 2006-02-09
BRPI0414105A (pt) 2006-11-21
AP2006003536A0 (en) 2006-04-30
IL205600A0 (en) 2010-11-30
DK1664036T3 (da) 2012-02-13
US7776885B2 (en) 2010-08-17
ATE539077T1 (de) 2012-01-15
US20100273794A1 (en) 2010-10-28
CY1112321T1 (el) 2015-12-09
BRPI0414105B1 (pt) 2018-08-14
NL1026959A1 (nl) 2005-03-07
EP1664036A1 (en) 2006-06-07
KR100738784B1 (ko) 2007-07-12
OA13248A (en) 2007-01-31
GT200400174A (es) 2005-05-02
RS20060145A (en) 2008-06-05
UA86204C2 (uk) 2009-04-10
WO2005021539A1 (en) 2005-03-10
US20050148573A1 (en) 2005-07-07
IL173705A0 (en) 2006-07-05
AU2004268840A1 (en) 2005-03-10
JP3983269B1 (ja) 2007-09-26
HRP20120077T1 (hr) 2012-02-29
AP2184A (en) 2010-12-02
EA009457B1 (ru) 2007-12-28
TNSN06073A1 (en) 2007-10-03
ECSP066407A (es) 2006-09-18
ES2377484T3 (es) 2012-03-28
PE20050874A1 (es) 2005-10-26
UY28496A1 (es) 2005-04-29
GEP20084527B (en) 2008-11-10
AR045552A1 (es) 2005-11-02
BRPI0414105B8 (pt) 2021-05-25
JP2007533613A (ja) 2007-11-22
CR8267A (es) 2006-11-21
AU2004268840B2 (en) 2010-09-23
IL205599A0 (en) 2010-11-30
CN1845922A (zh) 2006-10-11
CA2537127A1 (en) 2005-03-10
PA8610601A1 (es) 2005-03-28
KR20060087540A (ko) 2006-08-02
ZA200601324B (en) 2007-05-30
CN100482659C (zh) 2009-04-29
EP1664036B1 (en) 2011-12-28
IL173705A (en) 2013-04-30
AU2004268840B9 (en) 2011-02-03
CA2537127C (en) 2011-04-05
SI1664036T1 (sl) 2012-03-30
MA28021A1 (fr) 2006-07-03
NO20061519L (no) 2006-06-01
NL1026959C2 (nl) 2006-01-23
EA200600327A1 (ru) 2006-08-25
HK1093338A1 (en) 2007-03-02
MXPA06002550A (es) 2006-06-20
PL1664036T3 (pl) 2012-04-30

Similar Documents

Publication Publication Date Title
TW200510332A (en) Benzimidazolone compounds having 5-HT4 receptor agonistic activity
TW200640915A (en) Oxyindole derivatives
TW200603796A (en) Benzimidazolone carboxylic acid derivatives
ATE449092T1 (de) Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors
CA2545092A1 (en) Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
JP6768674B2 (ja) 新規ベンズイミダゾール化合物およびその医薬用途
NZ602612A (en) Novel benzamide derivatives
JP5101639B2 (ja) アミド誘導体及びそれを含有する医薬組成物
JP5156806B2 (ja) アミド誘導体からなる医薬
DOP2004000986A (es) Compuestos de bencimidazolona que tienen actividad del receptor 5ht-4
TH106943A (th) สารประกอบเบนซิมิดาโซโลนที่มีแอคทิวิทีต่อต้าน 5-ht4 รีเซพเตอร์
TH106943B (th) สารประกอบเบนซิมิดาโซโลนที่มีแอคทิวิทีต่อต้าน 5-ht4 รีเซพเตอร์
TH76314A (th) สารอนุพันธ์แบบซิมิดาโซโลน คาร์บอกซิลิก แอซิด